{
    "root": "3466672c-1212-3459-e063-6294a90a1288",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Diclofenac Sodium",
    "value": "20250505",
    "ingredients": [
        {
            "name": "ALUMINUM HYDROXIDE",
            "code": "5QB0T2IUN0"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "POLYVINYL ACETATE PHTHALATE",
            "code": "58QVG85GW3"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SODIUM ALGINATE",
            "code": "C269C4G2ZQ"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "STEARIC ACID",
            "code": "4ELV7Z65AP"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "DICLOFENAC SODIUM",
            "code": "QTG126297Q"
        }
    ],
    "indications": "Carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac sodium delayed-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals\n \n  (see\n  \n   WARNINGS; Gastrointestinal Bleeding, Ulceration, and Perforation)\n \n  .\n\n \n                  Diclofenac sodium delayed-release tablets are indicated:\n                  \n                     for relief of the signs and symptoms of osteoarthritis\n                     for relief of the signs and symptoms of rheumatoid arthritis\n                     for acute or long-term use in the relief of signs and symptoms of ankylosing spondylitis",
    "contraindications": "Carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac sodium delayed-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals\n \n  (see\n  \n   WARNINGS; Gastrointestinal Bleeding, Ulceration, and Perforation)\n \n  .\n\n \n                  After observing the response to initial therapy with diclofenac sodium delayed-release tablets, the dose and frequency should be adjusted to suit an individual patient’s needs.\n                  For the relief of osteoarthritis, the recommended dosage is 100 mg/day to 150 mg/day in divided doses (50 mg twice a day or three times a day, or 75 mg twice a day).\n                  For the relief of rheumatoid arthritis, the recommended dosage is 150 mg/day to 200 mg/day in divided doses (50 mg three times a day. or four times a day, or 75 mg twice a day).\n                  For the relief of ankylosing spondylitis, the recommended dosage is 100 mg/day to 125 mg/day, administered as 25 mg four times a day, with an extra 25-mg dose at bedtime if necessary.\n                  Different formulations of diclofenac (diclofenac sodium delayed-release tablets, USP; diclofenac sodium extended-release tablets, USP; diclofenac potassium immediate-release tablets) are not necessarily bioequivalent even if the milligram strength is the same.",
    "warningsAndPrecautions": "75 mg — Each white, round, enteric-coated tablet printed with\n \n   on one side and 551 on the other side with black ink contains 75 mg of diclofenac sodium, USP. Tablets are supplied in bottles of:\n\n \n                  NDC 55289-150-10 Bottles of 10\n                  NDC 55289-150-15 Bottles of 15\n                  NDC 55289-150-20 Bottles of 20\n                  NDC 55289-150-28 Bottles of 28\n                  NDC 55289-150-30 Bottles of 30\n                  NDC 55289-150-60 Bottles of 60\n                  Store at 25ºC (77ºF); excursions permitted to 15º to 30ºC (59º to 86ºF). Protect from moisture.\n                  Dispense in a tight, light-resistant container as defined in the USP.\n                  Dispense with Medication Guide available at: www.tevausa.com/medguides",
    "adverseReactions": "Diclofenac sodium delayed-release tablets are contraindicated in the following patients:\n                  \n                     Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product\n  \n   (see\n   \n    WARNINGS; Anaphylactic Reactions,\n   \n    Serious Skin Reactions)\n  \n   .\n \n  \n                     History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients\n  \n   (see\n   \n    WARNINGS; Anaphylactic Reactions,\n   \n    Exacerbation of Asthma Related to Aspirin Sensitivity)\n  \n   .\n \n  \n                     In the setting of coronary artery bypass graft (CABG) surgery\n  \n   (see\n   \n    WARNINGS; Cardiovascular Thrombotic Events)\n  \n   ."
}